Pioglitazone 15 mg (Generic)

Product Overview

Pioglitazone 15 mg is a prescription oral medication indicated for the management of type 2 diabetes mellitus. It is manufactured by USV Pvt. Ltd. and supplied in a convenient strip containing ten tablets. The product is available in multiple pack sizes, including 60, 90, and 120 tablets, allowing patients and clinicians to select the most appropriate supply for ongoing therapy. Each tablet delivers 15 mg of pioglitazone, a member of the thiazolidinedione class, which functions by improving insulin sensitivity in peripheral tissues. This medication is intended to be used in conjunction with a healthy diet and regular physical activity to achieve optimal glycemic control.

What is Pioglitazone 15 mg

Pioglitazone 15 mg belongs to the pharmacological class of thiazolidinediones (TZDs). The active ingredient, pioglitazone, acts primarily as a selective agonist for the peroxisome proliferator‑activated receptor gamma (PPAR‑γ). Activation of this nuclear receptor modulates gene expression pathways that enhance insulin signaling and glucose uptake in adipose, muscle, and hepatic tissues. Because it does not stimulate insulin secretion, pioglitazone does not cause hypoglycemia when used as monotherapy, but it may increase the risk of weight gain and fluid retention. The drug is marketed under various brand names and is also available as a generic tablet strength of 15 mg.

Uses and Benefits

The primary use of pioglitazone 15 mg is to improve glycemic control in adults with type 2 diabetes who have not achieved adequate glucose regulation through diet and exercise alone. Clinical studies have demonstrated that pioglitazone reduces HbA1c levels by approximately 0.5 to 1.0 percent when added to metformin or sulfonylurea therapy. In addition to its glucose‑lowering effect, pioglitazone has been associated with favorable changes in lipid profiles, including modest reductions in triglycerides and modest increases in high‑density lipoprotein (HDL) cholesterol. Some patients also experience a delay in the progression of beta‑cell dysfunction, which may preserve endogenous insulin secretion over time.

How It Works

At the molecular level, pioglitazone binds to the PPAR‑γ receptor, a nuclear receptor that regulates transcription of genes involved in glucose and lipid metabolism. Activation of PPAR‑γ leads to increased expression of insulin‑sensitive genes, such as GLUT4 transporters, which facilitate glucose uptake from the bloodstream into muscle and adipose tissue. This mechanism enhances peripheral insulin sensitivity without directly stimulating insulin release from pancreatic beta cells. Consequently, pioglitazone helps lower fasting and post‑prandial glucose concentrations, reduces hepatic glucose production, and contributes to a more favorable metabolic profile.

Dosage Guidelines

The recommended initial dosage of pioglitazone 15 mg is one tablet taken orally once daily, with or without food. Healthcare providers may adjust the dose based on individual patient response, renal function, and concomitant antidiabetic agents. In many treatment regimens, the dose can be titrated up to a maximum of 30 mg per day, administered as a single 30 mg tablet or two 15 mg tablets, depending on the formulation available. For patients with moderate renal impairment (eGFR 30–60 mL/min/1.73 m²), the starting dose should be 15 mg once daily, and dose escalation should be done cautiously. It is essential to follow the prescribing clinician’s instructions and to undergo periodic assessment of glycemic control, liver enzymes, and cardiac status.

Side Effects

Like all prescription medications, pioglitazone 15 mg can be associated with adverse effects. The most frequently reported side effects include weight gain, peripheral edema, and mild to moderate increases in serum creatinine. Less common but clinically significant risks involve fluid retention that may exacerbate congestive heart failure, hepatic enzyme elevations, and an increased incidence of bone fractures, particularly in women. Rarely, severe hepatic reactions such as cholestatic jaundice have been reported. Patients should be advised to report new or worsening shortness of breath, swelling of the ankles or feet, and any signs of liver dysfunction, such as dark urine, persistent nausea, or yellowing of the skin and eyes.

Warnings and Precautions

Pioglitazone is contraindicated in individuals with a history of hypersensitivity to the drug or any of its excipients. It should not be used in patients with severe heart failure (NYHA Class III or IV) or those with an active liver disease, including hepatitis or hepatic cirrhosis. Caution is advised in patients with a history of bladder cancer, as epidemiological data have suggested a possible increased risk. Routine laboratory monitoring should include liver function tests at baseline and periodically thereafter, as well as assessment of renal function. Concomitant use with insulin or strong sulfonylureas may increase the risk of hypoglycemia, requiring dose adjustments of the accompanying medication. Women of reproductive potential should discuss pregnancy planning with their healthcare provider, as the safety of pioglitazone during pregnancy and lactation has not been fully established.

Frequently Asked Questions

Question: Can pioglitazone 15 mg be used as a standalone therapy for diabetes?

Answer: Yes, pioglitazone can be prescribed as monotherapy when lifestyle modifications alone are insufficient to control blood glucose. However, many clinicians combine it with other oral agents such as metformin to achieve greater HbA1c reductions.

Question: How long does it take to see a reduction in HbA1c after starting pioglitazone?

Answer: Clinical trials have shown that a measurable decrease in HbA1c can be observed within 4 to 8 weeks of consistent daily use, with maximal effect typically reached after 12 weeks.

Question: Is weight gain inevitable when taking pioglitazone?

Answer: Weight gain is a common side effect, with average increases of 2 to 5 kilograms over several months. The magnitude of weight gain can vary among individuals and may be mitigated by diet and exercise.

Question: Does pioglitazone interact with other medications?

Answer: Pioglitazone may interact with drugs that affect hepatic enzymes, such as certain antifungals and antibiotics, potentially altering its plasma levels. It is also known to increase the hypoglycemic effect of insulin and some sulfonylureas, requiring dose adjustments.

Question: Can pioglitazone be taken by patients with kidney disease?

Answer: Pioglitazone can be used in patients with mild to moderate renal impairment, but dose reduction is recommended for those with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m². It is not recommended for patients with severe renal impairment or those on dialysis.

For authoritative prescribing information, refer to the FDA label (FDA.gov) and the National Institutes of Health (NIH Bookshelf). Additional details are available on MedlinePlus (MedlinePlus).